GTCM
PCVX icon

Gyon Technologies Capital Management’s Vaxcyte PCVX Stock Holding History

Gyon Technologies Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-5,669
Closed -$272K – 300
2022
Q4 		$272K Buy
+5,669
New +$222K 0.1% 185
2022
Q3 		– Sell
-27,105
Closed -$590K – 551
2022
Q2 		$590K Buy
+27,105
New +$627K 0.17% 152
2022
Q1 		– Sell
-31,342
Closed -$746K – 489
2021
Q4 		$746K Buy
+31,342
New +$729K 0.14% 206

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Gyon Technologies Capital Management's PCVX Position: Q1 2023 in Review

Gyon Technologies Capital Management sold out of Vaxcyte (PCVX) in Q1 2023, closing a stake of 5,669 shares — an estimated $272K sold.

Gyon Technologies Capital Management first reported a position in PCVX in Q4 2021 and held it in 3 quarters. The position peaked at $746K in Q4 2021. 187 funds tracked by Wall St. Rank hold PCVX as of Q1 2023.

  • Gyon Technologies Capital Management reported no remaining Vaxcyte position as of Q1 2023 after selling out during the quarter.
  • Gyon Technologies Capital Management sold 5,669 Vaxcyte shares in Q1 2023, an estimated $272K.
  • Gyon Technologies Capital Management first reported a position in Vaxcyte in Q4 2021 and held it in 3 quarters.
  • Gyon Technologies Capital Management's Vaxcyte position peaked at $746K in Q4 2021.
  • 187 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2023.

Based on Gyon Technologies Capital Management's 13F filing for Q1 2023.